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Systemic treatment of patients 
with metachronous peritoneal 
carcinomatosis of colorectal origin
T. R. van Oudheusden1,2, L. G. Razenberg2,3,  Y. R. van Gestel2, G. J. Creemers3, 
V. E. Lemmens2,4 & I. H. de Hingh1
Combining chemotherapy and targeted therapies has resulted in an enhanced survival in metastatic 
colorectal cancer (mCRC) patients. However, the result of this palliative treatment in patients with 
metachronous peritoneal carcinomatosis (PC) remains unknown. The current population-based study 
aims to investigate the use and effect of palliative systemic treatment in patients with metachronous 
PC of colorectal origin. Data on metachronous PC were collected between 2010 and 2011 for all patients 
who were diagnosed with M0 colorectal cancer between 2003 and 2008 in the Dutch Eindhoven Cancer 
Registry. Patient demographics and detailed data on chemotherapeutic treatment were collected and 
compared. Ninety-two patients with metachronous PC received chemotherapy in a palliative setting 
compared to 94 patients without treatment. In 36 patients, Bevacizumab was added to the treatment 
(39%). Overall survival was 3.4, 13, and 20.3 months in the no treatment, systemic treatment and 
systemic treatment + Bevacizumab respectively (P < 0.001). Male gender was a positive predictor and 
right sided primary tumor location a negative predictor of receiving bevacizumab. Approximately 40% 
of patients with metachronous PC received bevacizumab in addition to chemotherapy. Treatment with 
systemic chemotherapy in combination with bevacizumab may increase survival in a patients with 
metachronous colorectal PC.
Overall survival for patients with colorectal peritoneal carcinomatosis (PC) is dismal and typically averages around 
6 months1. After the implementation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy 
(HIPEC), 5-year survival rates of up to 40% have been reported while some patients even appear to be cured2–4. 
Unfortunately, the majority of PC patients do not qualify for this aggressive treatment due to the presence of other 
distant metastases, a poor condition, advanced disease or other reasons. In these patients systemic treatment with 
palliative intent is used in increasing frequency5.
Improvements in the systemic treatment of patients with metastatic colorectal cancer (mCRC) have resulted 
in extended survival. Currently, combining chemotherapy and targeted therapy is considered to be a standard of 
care for these patients6,7. However, no data from randomised controlled trials are available that have specifically 
addressed systemic treatment in PC patients. The sparse data available are derived from small subgroup analyses 
and population-based data8–10. Without exception, these studies show improved survival and support a role for 
modern combination therapy. These studies concern patients with synchronous PC where the primary tumor 
and PC were diagnosed simultaneously. However, in at least half of the patients, PC is diagnosed metachronously, 
after initial curative treatment for colorectal cancer11. So far, no data are available on the use and effect of palliative 
modern chemotherapy with or without targeted therapies in the latter group of patients. Therefore, the aim of the 
current population-based study is to investigate the use and effect of palliative systemic treatment in patients with 
metachronous PC of colorectal origin.
Methods
Patient selection. Data concerning patients presenting with metachronous PC of colorectal origin were 
extracted from the Eindhoven Cancer Registry that collects all data of patients with newly diagnosed cancer in 
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the Southern part of the Netherlands10. This area comprises approximately 2.4 million inhabitants and has 10 
community hospitals, 6 pathology departments and 2 radiotherapy institutions. All data are registered by trained 
registry managers who prospectively collect patient and tumor characteristics from medical charts.
Data on metachronous metastases were additionally collected between 2010 and 2011 for all patients who were 
diagnosed with M0 colorectal cancer between 2003 and 2008 in the Dutch Eindhoven Cancer Registry. Survival 
data were available until January 2014. Metachronous PC was defined as an interval of at least 3 months between 
primary tumor and PC diagnosis. Patient demographics and details concerning chemotherapeutic treatment and 
Bevacizumab (being the standard choice for targeted therapies at time of the current study) were collected and 
compared. Patients that underwent curative surgery for PC (CRS + HIPEC) were excluded from this study. Patients 
receiving targeted therapy prior to PC diagnosis and those who did not undergo a curative primary tumor resection 
were excluded from the analyses. Treatment and decisions were performed in accordance with national guidelines 
and regulations. The study protocol was approved and carried out in accordance with the Medical research Ethics 
Committees United (MEC-U).
Statistical analysis. Patient and tumor characteristics were compared between patients with or with-
out systemic treatment using the Chi square test. Next, the percentages of patients who additionally received 
Bevacizumab were calculated among those that received systemic treatment. Univariable and multivariable 
logistic regression analysis were used to identify predictors of treatment with Bevacizumab. Only variables with 
P < 0.10 in the univariate analysis were included in the multivariable analysis. The predictors were depicted as 
odds ratios with their 95% confidence intervals. The effect of systemic treatment on mortality was investigated 
using multivariable cox regression analyses and depicted as hazard ratios. Survival was determined using the 
Kaplan-Meier method and compared using a Log-rank test. Survival was defined as time from diagnosis of PC 
to death or end of follow up period (January 2014). All tests were two sided and p-value < 0.05 was considered 
to be significant. Statistical analyses were performed using SAS/STAT statistical software (SAS system 9.3, SAS 
Institute, Cary, North Carolina, USA).
Results
Altogether, 1042 patients with primary colorectal cancer diagnosed between 2003 and 2008 developed metachro-
nous metastases up until 2011. From these patients, 195 (19%) were diagnosed with metachronous PC and 101 
among them (52%) received systemic treatment in a palliative setting. Nine of the latter patients were excluded 
from further analysis since they received targeted therapy prior to diagnosis of PC. Of the remaining patients, 
36/92 patients (39%) received systemic treatment including Bevacizumab (Fig. 1).
Treatment & patient characteristics. Patient and tumor characteristics were compared between patients 
with or without systemic treatment (Table 1). Patients receiving systemic treatment were younger than those 
Figure 1. Study population. 
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receiving no treatment (67% vs. 31% with age < 70, P < 0.01). Also, they displayed less comorbidities (48% vs. 
68%, P < 0.01) and were more often diagnosed with other distant metastases (65% vs. 50%, P = 0.04). Gender, 
tumor differentiation, location, histology or T and N-stage did not differ between the two groups.
Table 2 shows the percentages of patient and tumor characteristics for those receiving additional Bevacizumab 
treatment among the total group of patients receiving systemic treatment. The multivariable odds ratios (OR’s) are 
provided for variables with a P-value < 0.10 in the univariate analysis. Among males, 51% received Bevacizumab 
compared to 26% among females (P = 0.01). In the age category below 70, 48% received Bevacizumab compared 
to 20% above 70 (P = 0.01). The group of patients without comorbidities received Bevacizumab more often (42% 
vs. 30%, P = 0.07). Regarding the primary tumor location, patients with left, right, rectum/rectosigmoid and over-
lapping/NOS as primary location received Bevacizumab in 60, 42, 30 and 33% of cases (P = 0.01).
The remaining factors tumor differentiation, histology, T-stage, N-stage and M-stage were not significantly 
different in the groups. Calculation of odds ratio’s showed male gender to be a positive predictor (OR 2.68, 95% CI 
1.0–7.4) and right sided primary tumor location (OR 0.20, 95% CI 0.1–0.6) to be a negative predictor for treatment 
with Bevacizumab.
Survival. Median overall survival of the entire PC group was 7.2 months (95% CI 5.2–9.4 months). Median 
overall survival was only 3.4 months (95% CI 2.5–4.9 months) in patients who did not receive systemic treatment, 
13.0 months (95% CI 9.5–16.0 months) for patients who received systemic chemotherapy only and 20.3 months 
(95% CI CI13.7–29.3 months) for patients treated with chemotherapy and Bevacizumab (P < 0.001) (Fig. 2). 
Variable
No systemic 
treatment (%)
Systemic 
treatment (%) P-value
N = 94 N = 92
Gender
 Female 54 (57.4) 43 (46.7) 0.14
 Male 40 (42.6) 49 (53.3)
Age (years)
 < 70 29 (30.9) 62 (67.4) <0.01
 > 70 65 (69.1) 30 (32.6)
Comorbidity
 No 30 (31.9) 48 (52.2) <0.01
 Yes 64 (68.1) 44 (47.8)
Tumor differentiation
 Good 4 (4.3) 5 (5.4) 0.95
 Moderate 53 (56.4) 52 (56.5)
 Poor/undifferentiated 23 (24.5) 20 (21.7)
 Unknown 14 (14.9) 15 (16.3)
Primary Location
 Left 32 (34.0) 41 (44.6) 0.10
 Right 46 (48.9) 37 (40.2)
 Rectum/rectosigmoid 15 (16.0) 9 (9.8)
 Overlapping/NOS 1 (1.1) 5 (5.4)
Histology
 Mucinous 21 (22,3) 26 (28.3) 0.62
 Adenocarcinoma 70 (74.5) 64 (69.6)
 Signet ring cell 2 (2.1) 2 (2.2)
 Unknown 1 (1.1) 0
T-stage
 T1,T2 6 (6.4) 3 (3.3) 0.57
 T3 65 (69.1) 68 (73.9)
 T4 23 (24.5) 21 (22.8)
N-stage
 N0 29 (30.9) 36 (39.1) 0.15
 N1 31 (33.0) 35 (38.0)
 N2 32 (34.0) 21 (22.8)
 NX 2 (2.1) 0
M-status
 PC only 47 (50.0) 32 (34.8) 0.04
 PC + distant 47 (50.0) 60 (65.2)
Table 1.  Patient and tumor characteristics in patients treated with and without systemic chemotherapy.
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Variable Systemic treatment Bevacizumab (%) Chi Square P-value OR (95% CI)
Gender
 Female 43 11 (25.6) 0.01 ref
 Male 49 25 (51.0) 2.68 (1.0–7.4)
Age (years)
 < 70 62 30 (48.4) 0.01 ref
 > 70 30 6 (20) 0.37 (0.1–1.2)
Comorbidity
 No 48 23 (41.8) 0.07 ref
 Yes 44 13 (29.5) 0.39 (0.1–1.2)
Tumor differentiation
 Good 5 3 (60.0) 0.56
 Moderate 52 22 (42.3)
 Poor/undifferentiated 20 6 (30.0)
 Unknown 15 5 (33.3)
Primary Location
 Left 41 21 (51.2) 0.01 ref
 Right 37 7 (18.9) 0.20 (0.1—0.6)
 Rectum/rectosigmoid 9 5 (55.6) 0.72 (0.2–3.5)
 Overlapping/NOS 5 3 (60.0) 0.90 (0.1–6.7)
Histology
 Mucinous 26 7 (19.4) 0.32
 Adenocarcinoma 64 28 (43.8)
 Signet ring cell 2 1 (50.0)
0
T-stage
 T1,T2 3 1 (33.3) 0.66
 T3 68 25 (36.8)
 T4 21 10 (47.6)
N-stage
 N0 36 14 (38.9) 0.78
 N1 35 15 (42.9)
 N2 21 7 (33.3)
M-status
 PC only 32 15 (68.2) 0.27
 PC + distant 60 21 (35.0)
Table 2.  Percentages and multivariable predictors of patients treated with Bevacizumab among those 
treated with systemic chemotherapy. OR: odds ratio. CI; confidence interval. *The included variables were 
determined based on univariate logistic regression variables with P < 0.10.
Figure 2. Kaplan Meier of survival of patients without systemic treatment (blue), with systemic treatment 
(red) or systemic treatment and bevacizumab (green). 
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Next, survival of patients receiving chemotherapy was compared to patients receiving both chemotherapy and 
Bevacizumab with median survival being significantly longer in the group receiving both treatments (P = 0.04).
Predictors of death for patients with metachronous PC are shown in Table 3 and presented as hazard ratios 
(HR). Age above 70 was associated with an increased risk of death (HR 1.86, 95% CI 1.29–2.68). The administra-
tion of both chemotherapy (HR 0.51, 95% CI 0.35–0.73) and chemotherapy with bevacizumab (HR 0.35, 95% CI 
0.22–0.56) was associated with a decreased risk of death. When comparing chemotherapy only to chemotherapy 
and Bevacizumab, the hazard ratio was 0.69 (95% CI 0.42–1.12).
Discussion
The data reported in this study suggest that palliative chemotherapy provided to patients diagnosed with metachro-
nous peritoneal carcinomatosis of colorectal origin improved survival. Furthermore, the addition of Bevacizumab 
might improve survival even further.
While a positive effect of adding targeted therapy to chemotherapy has previously been established for synchro-
nous PC10, it remained unknown if such treatment would also benefit patients in the metachronous setting. These 
patients differ from the synchronous group since they have already undergone surgery for the primary tumor with 
curative intent and developed the metastases during follow up. Moreover, it has been shown that survival after 
metachronous metastases of colorectal origin is different compared to the synchronous setting with better results 
in the metachronous subgroup of patients12. This difference might be attributable to a more aggressive tumor 
biology in those patients presenting with synchronous metastases13. The current data showed that the addition of 
Bevacizumab to chemotherapy resulted in a median survival of 20 months compared to 13 months for patients 
treated with chemotherapy only. Bevacizumab was the standard choice of treatment for metastasised colorectal 
cancer during the course of this study and therefore the observed effect may be specifically attributed, at least in 
part, to this biological agent. However, several other factors which probably play a role in patient eligibility for the 
various palliative treatment options may affect outcome as well.
Metachronous PC is diagnosed in 4% of patients with colorectal carcinoma and is know to result in a median 
survival of only a few months14–16. The introduction of cytoreductive surgery and HIPEC during the last two dec-
ades has, in selected groups, resulted in a median survival of up to 60 months after diagnosis17,18. Unfortunately, 
the majority of patients cannot benefit from this particular treatment since patients have to be fit for surgery with 
limited peritoneal disease and an absence of distant metastases19. Therefore, additional palliative treatment options 
must be investigated for these patients.
The use of targeted monoclonal antibodies has improved overall and progression free survival in mCRC20,21. 
However, these improvements have been mainly demonstrated in patients with metastases to the liver or lung. 
These organs are well vascularised making intravenous chemotherapy readily available at these metastatic sites as 
opposed to peritoneal deposits, which are located in a more isolated part of the human body. Klaver et al. demon-
strated this phenomenon by analysing two trials that included mCRC patients in the Netherlands9: the survival 
benefit of systemic chemotherapy with or without targeted therapies is significantly less in PC than in non-PC 
metastasized patients. A similar analysis by Franko et al. led to similar conclusions8. However, these trials have in 
common that a relatively small percentage of metastasized patients had PC.
Recently, results of treatment with chemotherapy and targeted therapies have also emerged specifically for 
PC. Zani et al. compared a PC group treated with modern chemotherapy including targeted therapies to a group 
treated with outdated regimens and showed an increased median survival of 16.3 vs. 8.9 months in the former22. 
Variable Dead (%) P-value HR (95% CI)
Gender
 Male 91.0 0.86 ref
 Female 91.8 1.13 (0.82–1.56)
Age (years)
 < 70 86.8 0.03 ref
 > 70 95.8 1.86 (1.29–2.68)
Comorbidity
 No 88.5 0.22 ref
 Yes 93.5 1.18 (0.85–1.56)
Primary tumor location
 Left 90.4 0.76 ref
 Right 91.6 0.97 (0.68–1.37)
 Rectum/recto sigmoid 95.8 1.73 (1.05–2.85)
 Overlapping/NOS 83.3 1.76 (0.68–4.55)
Systemic therapy
 No systemic therapy 95.7 0.10 ref
 Chemotherapy only 87.5 0.51 (0.35–0.73)
 Chemotherapy + Bevacizumab 86.1 0.35 (0.22–0.56)
Table 3.  Predictors of death among colorectal cancer patients with metachronous PC (COX-regression 
analyses). HR: odds ratio. CI; confidence interval.
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Another recent study by Chua et al. described a cohort of 294 patients with PC in a palliative setting. Combination 
chemotherapy regimens (5-FU based with oxaliplatin or irinotecan) resulted in a median survival rate of 15 months 
compared to 11 months using single agent 5FU regimens23. Interestingly, median survival appeared to be further 
increased by adding targeted therapies such as bevacizumab, cetuximab or panitumumab, resulting in a median 
survival of 23 months. Both studies included a mixed population of metachronous and synchronous presentation 
of PC. In addition, similar findings have been reported in a synchronous PC only cohort, with an increased median 
survival of 10.1 to 18.2 months after the addition of targeted therapies10.
Certain biases could not be evaded in the evaluation of the present cohort leading to a suggestion of increased 
survival when targeted therapies were added to palliative chemotherapy. The majority of patients receiving targeted 
therapies had less comorbidities and were younger, both conditions favouring enhanced survival. Nonetheless, 
in terms of hazard ratios, combining targeted therapies with chemotherapy proved to be a protective factor 
in multivariable analysis. However, when leaving out the patients who received no treatment, the addition of 
Bevacizumab did not significantly decrease the chance of death probably due to small sample size. Therefore the 
role of Bevacizumab in the treatment of metachronous PC from colorectal origin should be regarded as promising 
but needs further clinical investigation.
In addition, it stands to reason that considerations taken into account while deciding whether or not, to what 
extent and what type of chemotherapeutics and targeted therapies will be administered are patient and caretaker 
dependent24. Moreover, a significant proportion of patients had also other distant metastases. It is therefore uncer-
tain to what extent increased survival can be attributed to the treatment of the peritoneal deposits in these patients, 
especially so since the effectiveness of targeted therapies in non-peritoneal metastases is supported by stronger 
evidence. Still, since many patients receive palliative treatment because of the presence of distant metastases they 
are a common phenomenon and therefore reflect clinical daily practice. Lastly, the extent of disease is impossible to 
assess since diagnostic modalities lack the ability to adequately estimate severance of disease. However, all patients 
were in a palliative setting, which means that either the patient condition wouldn’t allow surgery, or the presence 
of either extra-abdominal metastases or severe intra-abdominal metastases made surgery contra-indicated.
To our knowledge, no studies have reported on the added value of Bevacizumab to palliative chemotherapy in 
patients with metachronous PC. The results of the current study suggest that treatment with palliative systemic 
chemotherapy especially in combination with Bevacizumab may significantly improve survival in these patients. 
However, due to the nature of this population-based study potential selection bias is inevitably and the results 
should therefore be interpreted cautiously.
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